Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard acquired 5,580 shares of the company’s stock in a transaction dated Monday, September 19th. The stock was acquired at an average cost of $4.76 per share, for a total transaction of $26,560.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Argos Therapeutics Inc. (NASDAQ:ARGS) traded up 7.95% during trading on Wednesday, reaching $5.16. 187,655 shares of the company’s stock were exchanged. The firm’s market capitalization is $212.57 million. Argos Therapeutics Inc. has a 52 week low of $1.61 and a 52 week high of $13.97. The stock has a 50-day moving average price of $4.80 and a 200 day moving average price of $5.96.
Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. Equities research analysts forecast that Argos Therapeutics Inc. will post ($1.55) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in ARGS. Sanders Morris Harris Inc. purchased a new position in shares of Argos Therapeutics during the first quarter valued at $907,000. Oxford Asset Management bought a new position in Argos Therapeutics during the second quarter worth approximately $353,000. Geode Capital Management LLC increased its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares in the last quarter. California State Teachers Retirement System bought a new position in Argos Therapeutics during the second quarter worth approximately $137,000. Finally, Bank of New York Mellon Corp increased its position in Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares in the last quarter. 11.05% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently commented on ARGS. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Monday, August 15th. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Friday, June 17th. FBR & Co lowered their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 11th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Monday, June 20th. Eight analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $11.50.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.